Gastrointestinal disorders Ulcers

Use treatment of gastrointestinal disorders (ulcerative colitis, Crohn s disease)... 

Inflammatory bowel disease is divided into two major gastrointestinal disorders ulcerative colitis (UC) and Crohn s disease. Both diseases are chronic and tend to be characterized by periods of exacerbations and remissions. Major differences between UC and Crohn s disease are differentiated by anatomic location and distribution. UC occurs in the colon and rectum, whereas Crohn s disease can occur throughout the gastrointestinal tract. UC tends to be continuous, diffuse, and mucosal Crohn s appears segmental, focal, and transmural. Fissures, strictures, abdominal masses, and pain are commonly associated with Crohn s. Classical symptoms of UC include chronic diarrhea with tenesmus, rectal bleeding, and abdominal pain. 

Monocytosis (>800/mm of blood) occurs with some infections (e.g., tuberculosis, histoplasmosis, toxoplasmosis, bacterial endocarditis, and salmonellosis), collagen vascular diseases (rheumatoid arthritis and systematic lupus erythematosus), gastrointestinal disorders (ulcerative cohtis and alcoholic liver disease), leukemias, and up to 60% of nonhematologic malignancies, whereas abnormally low monocyte concentrations occur in patients with hairy cell leukemia or aplastic anemia." ... 

Bismuth compounds were once employed for the treatment of amoebic dysentery, certain skin diseases, and several spirochetal diseases besides syphilis, but these substances are now seldom considered the dmgs of choice. Various insoluble preparations of bismuth, especially the subcarbonate, subnitrate, subgaHate, subcitrate, and subsahcylate, are stiU employed for the treatment of ulcers and other gastrointestinal disorders, even though use for these purposes is often supported largely by tradition. With a few possible exceptions, it is now difficult to justify the presence of bismuth compounds in a modem therapeutic armamentarium. A review of the biological activity of organobismuth compounds has been pubHshed (179). 

Gastrointestinal disorders (e.g. dyspepsia), gastrointestinal erosion with bleeding, ulceration and perforation... 

Gastrointestinal disorders Decreased inflammation Crohn disease, ulcerative colitis... 

Mild and transient gastrointestinal disorders, namely nausea, vomiting, diarrhea or anorexia, were observed in 30-40% of patients, and their severity is typically dose-related (20). Dryness or inflammation of the oropharynx, and moderate stomatitis were sometimes noted, but severe painful oral ulcers recurring after interferon alfa re-administration have been reported (241). More severe forms of digestive disease have been described in isolated case histories with microscopic colitis and the occurrence or the exacerbation of ulcerative colitis (SED-13, 1094) (SEDA-21, 372). 

Thompson. J. H. Gastrointestinal disorders—peptic ulcer disease, in Rubin. A. A. (ed.). Scorch for New Drugs. Medicinal ResearL ii Senes, vol. 6. New York. Marcel Dekker. 1972. p. M5. 

GEA 6414 tolfenamic acid, gefarnate (ban, inn] (geranyl farnesylacetate) is a tetradecatrienoate, which has been used as a gastric SECRETION INHIBITOR and ANTIIJLCEROGENIC for the treatment of peptic ulcers and other gastrointestinal disorders. GelTears carbomer. 

GASTRIC PROTON PUMP INHIBITOR, a (H /K ) ATPASE INHIBITOR. It can be used as an ANTIULCEROGENIC in the treatment of gastric ulcers and other gastric acid-related gastrointestinal disorders. It can be used in combination with amoxicillin for eradication of gastric Helicobacter pylori infection. Larafen ketoprofen. 

Potentially, it can be used as an antiulcerogenic in the treatment of gastric ulcers and other gastric acid-related gastrointestinal disorders. 

---